Substance

ID:353

Names and Identifiers
IUPAC name
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6H,6aH,7H,8H,10aH-benzo[c]isochromen-1-ol
Brand Name
Dea No. 7370Deltanyne&DeltaDea No. 7369Dronabinol [Usan:Inn]9-THCdelta-9-THCDronabinolum [Latin]9-tetrahydrocannabinolMarinolAbbott 40566Dronabinoldelta-9-tetrahydrocannabinol
Synonyms
Dronabinol
IUPAC Traditional name
marinol
Registration numbers
CAS Number
PubChem CID
PubChem SID
Properties
Physical Property
Hydrophobicity(logP)
5.648
Solubility
2.8 mg/ml
Molecule Details
Drug Groups
illicit; approved
Description
A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. Dronabinol is a synthetic form of delta-9-THC. [PubChem]
Indication
For the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
Pharmacology
Marinol may has complex effects on the central nervous system (CNS), including cannabinoid receptors. Dronabinol may inhibit endorphins in the emetic center, suppress prostaglandin synthesis, and/or inhibit medullary activity through an unspecified cortical action.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic
Absorption
90 - 95%
Half Life
Alpha phase: approximately 4 hours; Beta phase: 25-36 hours
Protein Binding
97%
Elimination
Dronabinol and its biotransformation products are excreted in both feces and urine.
Distribution
* 10 L/kg
Clearance
* 0.2 L/kg-hr
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data